Viewing nowSubaroadi Tablet 5 mg (Rosuvastatin Calcium (Unformulated))
Rosuvastatin Calcium Micronized 5.2mg
Orally disintegrating Tablet · Prescription medication
BC World Pharmaceutical Co., Ltd.

MFDS item code 202107780 · Approved 2021.12.02 · Insurance code 653103710
Treatment of dyslipidemia, inhibition of the progression of atherosclerosis, and prevention of cardiovascular disease
This medication is used when primary hypercholesterolemia and mixed hyperlipidemia cannot be managed by diet and exercise. It is also used as an adjunct to diet for patients with homozygous familial hypercholesterolemia or dysbetalipoproteinemia. This drug lowers total cholesterol and LDL cholesterol levels, delaying the progression of atherosclerosis, and is helpful for pediatric patients with familial hypercholesterolemia, particularly children. It is used in high-risk patients with elevated high-sensitivity C-reactive protein levels to reduce the risk of stroke, myocardial infarction, and arterial revascularization. It is effective for a variety of hyperlipidemia and cardiovascular disease risk reduction.
This medicine is an orally disintegrating tablet. Place it on the tongue, allow it to dissolve, and take it without water. 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which is sufficient to control the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; the dose may be increased to a maximum of 20 mg daily. 3. Elderly patients: No dose adjustment is necessary. 4. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering this medicine at a dose of 20 mg to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of this medicine at a dose of 40 mg is contraindicated in some of these patients.
2. Pediatric patients with heterozygous familial hypercholesterolemia (aged 10 to 17 years): The usual dose range is 5 mg to 20 mg once daily. (There are no clinical data on doses greater than 20 mg in pediatric patients.) Children under 10 years: Safety and efficacy have not been established.
This medication should not be used in certain patients. For example, patients who are allergic to any component of this drug, those with severe liver impairment, and individuals with muscle disorders should not take this medication. Additionally, patients with severely impaired kidney function, as well as pregnant or nursing women, should not take this drug. Women of childbearing potential can only use this drug if they are highly unlikely to become pregnant and fully understand the risks to the fetus. Patients susceptible to muscle disease, such as those with moderate kidney impairment, hypothyroidism, a family history or genetic history of muscle disorders, or those who consume large amounts of alcohol should avoid high doses of this medication. This medication should be used cautiously in patients with a history of liver disease or excessive alcohol intake, and regular liver function tests before and during treatment are recommended. Muscle-related side effects, such as myalgia, myopathy, and rarely rhabdomyolysis, may occur, so any unusual symptoms related to muscles should be reported to healthcare professionals immediately. Especially if muscle pain is accompanied by fatigue or fever, prompt testing is necessary. In cases of acute renal failure or serious medical conditions, the use of this medication should be discontinued. Moreover, this medication can rarely cause severe muscle weakness or ophthalmoplegia, so if such symptoms occur, discontinue use immediately. This medication can interact with several other drugs, so inform healthcare professionals if you are taking other medications. In particular, co-administration with certain antiviral drugs, immunosuppressants, or fibrates can increase the risk of muscle side effects. When taking high doses, regular tests of kidney function are necessary, and Asian patients may need dosage adjustments due to increased systemic exposure. While on this medication, blood sugar levels can rarely increase or the risk of diabetes may rise, so patients with diabetes risk factors should regularly monitor their blood sugar. Pregnant or nursing women should not take this medication, and women of childbearing potential should use appropriate contraception, as this drug may harm the fetus or infant. In the event of overdose, there is no specific antidote, so treatment must be symptomatic, along with liver function and muscle enzyme testing. Dizziness may occur when driving or operating machinery, so caution is advised.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. It is best to maintain the storage temperature between 1 to 30 degrees Celsius to preserve the drug's effectiveness.
White to yellowish round orally disintegrating tablet
30 tablets/box [10 tablets/PTP × 3], 10 tablets/box [10 tablets/PTP × 1]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowRosuvastatin Calcium Micronized 5.2mg
Orally disintegrating Tablet · Prescription medication
BC World Pharmaceutical Co., Ltd.

Rosuvastatin Calcium Micronized 20.8mg
Tablet · Prescription medication
Daewoong Pharmaceutical Co., Ltd.

Rosuvastatin Calcium Micronized 5.2mg
Tablet · Prescription medication
Daiwoo Pharmaceutical Co., Ltd.

Rosuvastatin Calcium Micronized 10.4mg
Tablet · Prescription medication
Daewoong Pharmaceutical Co., Ltd.

Rosuvastatin Calcium Micronized 10.4mg
Tablet · Prescription medication
Hanin Pharmaceutical Co., Ltd.

Rosuvastatin Calcium Micronized 10.4mg
Tablet · Prescription medication
Myungjin Pharmaceutical Co., Ltd.

Rosuvastatin Calcium Micronized 5.2mg
Tablet · Prescription medication
Teragen Itex Co., Ltd.

Rosuvastatin Calcium Micronized 10.4mg
Tablet · Prescription medication
Teragen Etex Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.